Tamoxifen






7024 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 94084 Effects of tamoxifen on the binding and metabolism of testosterone by human prostatic tissue and plasma in vitro. J Endocrinol 1979 Dec 2
2 121266 [In vivo occupation of estrogen receptors by hydroxylated metabolites of tamoxifen]. C R Seances Acad Sci D 1979 Dec 10 1
3 191185 Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep 1976 Oct 2
4 201053 Progesterone interaction with estrogen and antiestrogen in the rat uterus--receptor effects. Steroids 1977 Aug 1
5 207880 Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health 1978 Mar-May 1
6 339802 Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med 1978 Jan 1
7 486127 Hormonal control of uteroglobin secretion in rabbit uterus: inhibition of uteroglobin synthesis and messenger ribonucleic acid accumulation by oestrogen and anti-oestrogen administration. Biochem J 1979 Jun 15 5
8 561688 Estrogen receptor translocation and replenishment by the antiestrogen tamoxifen. Endocrinology 1977 Oct 1
9 564384 Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 1978 Feb 6
10 638966 The use of antiestrogens tamoxifen and nafoxidine in the treatment of human breast cancer in correlation with estrogen receptor values. A phase II study. Cancer 1978 Mar 1
11 748014 Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978 Nov 4
12 798626 Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 1976 Oct 1
13 815505 Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin. J Endocrinol 1976 Feb 1
14 828517 Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 1976 Oct 3
15 908269 Anti-estrogenic compounds increase prolactin and growth hormone synthesis in clonal strains of rat pituitary cells. Endocrinology 1977 Oct 2
16 918118 Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer. Prog Clin Biol Res 1977 1
17 964206 Induction of uterine ornithine decarboxylase (ODC) by antiestrogens. Inhibition of estradiol-mediated induction of ODC: a possible mechanism of action of antiestrogens. Endocr Res Commun 1976 4
18 1024568 [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer]. Boll Soc Ital Biol Sper 1976 Oct 15 1
19 1314079 Opposite regulation of cAMP concentration in the quail oviduct and the mouse uterus by tamoxifen. Correlation with estrogen-antagonist and estrogen-agonist activity. J Steroid Biochem Mol Biol 1992 Mar 4
20 1315250 Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8). Endocrinology 1992 May 2
21 1321770 Evidence for a role for protein kinase C in the modulation of bombesin-activated cellular signalling in human breast cancer cells. Mol Cell Endocrinol 1992 Jun 1
22 1322240 Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992 Aug 1 4
23 1322985 A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin. J Med Chem 1992 Jul 24 2
24 1350452 Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 1992 3
25 1350760 Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 1992 Jun 1
26 1355980 Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 1992 5
27 1356014 Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J Steroid Biochem Mol Biol 1992 Sep 1
28 1359155 High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992 Dec 2 2
29 1360843 Immunohistochemical determination of P-glycoprotein in a rat mammary tumour treated with tamoxifen. In Vivo 1992 Sep-Oct 3
30 1373360 Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992 May 1
31 1380889 Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992 Sep 1 7
32 1381703 The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer 1992 Sep 9 6
33 1394142 Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res 1992 Oct 1 6
34 1403692 Halogenated analogues of tamoxifen: synthesis, receptor assay, and inhibition of MCF7 cells. J Pharm Sci 1992 Jul 2
35 1403784 Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. J Pharmacol Exp Ther 1992 Oct 1
36 1417009 [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer]. Gan To Kagaku Ryoho 1992 Oct 1
37 1418821 A note on the conformational flexibility of the antiestrogenic drug tamoxifen: preferred conformations in the free state and bound to the protein calmodulin. Acta Crystallogr B 1992 Aug 1 2
38 1419616 Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992 Oct 1
39 1421427 Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 1992 6
40 1423240 Modulation of the anti-proliferative signal of interferon-alpha by tamoxifen in U937 cells. Cancer Lett 1992 Oct 30 1
41 1426318 Ovarian steroids modulate human monocyte tumor necrosis factor alpha messenger ribonucleic acid levels in cultured human peripheral monocytes. Fertil Steril 1992 Oct 1
42 1434657 Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice. J Surg Oncol 1992 Dec 1
43 1465279 Variations in estrogen and progesterone receptor levels after short-term tamoxifen treatment in breast carcinoma. Oncology 1992 1
44 1483948 Recombinant human interferon-alpha 2a increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen. Jpn J Cancer Res 1992 Dec 3
45 1504439 A new variant of alpha-1-antitrypsin deficiency (Siiyama) associated with pulmonary emphysema. Intern Med 1992 May 1
46 1516065 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 1992 Sep 15 1
47 1517237 Identification of an estrogen response element in the 3'-flanking region of the murine c-fos protooncogene. J Biol Chem 1992 Sep 5 1
48 1525393 Recombinant interferon-alpha 2b affects proliferation, steroid receptors and sensitivity to tamoxifen of cultured breast cancer cells (CG-5). Anticancer Drugs 1992 Apr 2
49 1525595 Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin. Bone Miner 1992 Aug 1
50 1529443 The potentiation of 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity by tamoxifen in female CD1 mice. Toxicol Appl Pharmacol 1992 Sep 2